Wixela Inhub Side Effects
Generic name: fluticasone / salmeterol
Medically reviewed by Drugs.com. Last updated on Sep 14, 2023.
Note: This document contains side effect information about fluticasone / salmeterol. Some dosage forms listed on this page may not apply to the brand name Wixela Inhub.
Applies to fluticasone / salmeterol: inhalation aerosol liquid, inhalation disk, inhalation powder.
Serious side effects of Wixela Inhub
Along with its needed effects, fluticasone/salmeterol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking fluticasone / salmeterol:
- Black, tarry stools
- blurred vision
- burning, tingling, numbness, or pain in the hands, arms, feet, or legs
- decreased vision
- difficulty with breathing or swallowing
- eye pain
- fast heartbeat
- hives or welts, skin itching, rash, or redness
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- noisy breathing
- painful or difficult urination
- sensation of pins and needles
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- stabbing pain in the arms or legs
- swollen glands
- unusual bleeding or bruising
Incidence not known
- darkening of the skin
- decrease in height
- difficulty with moving
- facial hair growth in females
- fast, slow, pounding, or irregular heartbeat or pulse
- flushed, dry skin
- fruit-like breath odor
- full or round face, neck, or trunk
- heavy bleeding
- increased hunger
- increased thirst or urination
- large, flat, blue, or purplish patches in the skin
- loss of sexual desire or ability
- menstrual irregularities
- mental depression
- muscle pain or stiffness
- muscle wasting
- pain in the back, ribs, arms, or legs
- pain in the joints
- stomach pain
- unexplained weight loss
- unusual tiredness or weakness
- weight gain
Get emergency help immediately if any of the following symptoms of overdose occur while taking fluticasone / salmeterol:
Symptoms of overdose
- Chest pain or tightness
- decreased urine output
- dry mouth
- faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- general feeling of discomfort or illness
- high blood pressure
- loss of appetite
- mood changes
- numbness or tingling in the hands, feet, or lips
- sudden sweating
- trouble with sleeping
Other side effects of Wixela Inhub
Some side effects of fluticasone / salmeterol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Body aches or pain
- dryness of the throat
- high-pitched noise when breathing
- runny nose
- trouble with swallowing
- voice changes
- Cough-producing mucus
- irritation or inflammation of the eye
- muscle pain
- pain or tenderness around the eyes and cheekbones
- sleep disorders
- stuffy nose
- white patches in the mouth or throat or on the tongue
For Healthcare Professionals
Applies to fluticasone / salmeterol: inhalation aerosol, inhalation powder.
The most common events that occurred more frequently were nasopharyngitis, upper respiratory tract infection, nasal congestion, back pain, sinusitis, dizziness, nausea, pneumonia, candidiasis, and dysphonia.[Ref]
Very common (10% or more): Headache (up to 21%)
Common (1% to 10%): Migraine
Uncommon (0.1% to 1%): Tremor
Postmarketing reports: Paraesthesia, restlessness, compressed nerve syndrome, aphonia[Ref]
The incidence of pneumonia was higher in adult subjects with COPD older than 65 years compared with younger subjects with COPD (18% versus 14%).[Ref]
Very common (10% or more): Upper respiratory tract infections (up to 27%), pharyngitis (up to 13%), nasopharyngitis
Common (1% to 10%): Pneumonia, bronchitis, throat irritation, hoarseness, dysphonia, sinusitis, upper respiratory inflammation, viral respiratory infections, cough, rhinorrhea/postnasal drip, epistaxis, nasal congestion/blockage, laryngitis, unspecified oropharyngeal plaques, dryness of nose, lower respiratory signs and symptoms, lower respiratory infections, lower respiratory hemorrhage, congestion
Uncommon (0.1% to 1%): Dyspnea
Rare (less than 0.1%): Oropharyngeal angioedema, bronchospasm, paradoxical bronchospasm
Frequency not reported: Nose, and throat infections, laryngitis, nasal sinus disorders, nasal sinus disorders
Postmarketing reports: Paranasal sinus pain, rhinitis, throat soreness, tonsillitis, asthma, asthma exacerbation, chest congestion, chest tightness, tracheitis, wheezing, report of upper respiratory symptoms of laryngeal spasm, irritation, or swelling such as stridor or chocking[Ref]
Rare (less than 0.1%): Cardiac arrhythmias (including supraventricular tachycardia and extrasystoles)
Frequency not reported: Hematomas
Postmarketing reports: Ventricular tachycardia, pallor[Ref]
Common (1% to 10%): Contusions, wounds, eczema, dermatitis, dermatosis
Frequency not reported: Skin flakiness and acquired ichthyosis, disorders of sweat and sebum
Postmarketing reports: Ecchymoses, photodermatitis[Ref]
Common (1% to 10%): Oral and throat candidiasis, nausea and vomiting, gastrointestinal discomfort and pain, dental discomfort and pain, hyposalivation, gastrointestinal infections, disorders of hard tissue of teeth, abdominal discomfort and pain, oral abnormalities, gastrointestinal discomfort and pain, viral gastrointestinal infections, diarrhea
Rare (less than 0.1%): Esophageal candidiasis
Frequency not reported: Oral lesions
Postmarketing reports: Oral ulcerations, dyspepsia, xerostomia[Ref]
Common (1% to 10%): Allergies and allergic reactions[Ref]
Common (1% to 10%): Hypokalemia, weight gain
Uncommon (0.1% to 1%): Hyperglycemia
Frequency not reported: Fluid retention[Ref]
Common (1% to 10%): Muscle cramps, traumatic fractures, arthralgia, myalgia, arthralgia, articular rheumatism, muscle spasms, musculoskeletal inflammation, bone and skeletal pain, muscle injuries, soft tissue injuries
Common (1% to 10%): Allergic eye disorders, eye edema and swelling
Uncommon (0.1% to 1%): Cataract
Rare (less than 0.1%): Glaucoma
Common (1% to 10%): Candidiasis unspecified site, ear signs and symptoms, viral infections, bacterial infections, inflammation, bacterial reproductive infections
Rare (less than 0.1%): Angioedema, facial angioedema
Frequency not reported: Syncope, edema and swelling, dysmenorrhea, pain, unusual taste, lacerations
Postmarketing reports: Ear ache, fever[Ref]
Uncommon (0.1% to 1%): Cutaneous hypersensitivity reactions
Uncommon (0.1% to 1%): Anxiety, sleep disorders
Rare (less than 0.1%): Behavioral changes, including psychomotor hyperactivity and irritability (predominately in children)
Frequency not reported: Depression, aggression (predominantly in children)
Postmarketing reports: Agitation[Ref]
Rare (less than 0.1%): Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease bone mineral density
Frequency not reported: Hypothyroidism
Postmarketing reports: Hypercorticism[Ref]
Frequency not reported: Abnormal liver function tests[Ref]
Frequently asked questions
More about Wixela Inhub (fluticasone / salmeterol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (113)
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bronchodilator combinations
Related treatment guides
1. Brogden RN, Faulds D. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs. 1991;42:895-912.
2. Salmeterol. Med Lett Drugs Ther. 1994;36:37-9.
3. Product Information. Serevent (salmeterol). Glaxo Wellcome.
4. Nathan RA, Seltzer JM, Kemp JP, Chervinsky P, Alexander WJ, Liddle R, Mills R. Safety of salmeterol in the maintenance treatment of asthma. Ann Allergy Asthma Immunol. 1995;75:243-8.
5. Lorentzen KA, Vanhelmond JLM, Bauer K, Langaker KE, Bonifazi F, Harris TAJ. Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr. Respir Med. 1996;90:609-17.
6. Product Information. Advair Diskus (fluticasone-salmeterol). Glaxo Wellcome. 2001.
7. Cerner Multum, Inc. UK Summary of Product Characteristics.
8. Cerner Multum, Inc. Australian Product Information.
9. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA. 1994;271:1412-6.
10. Kemp JP, Bierman CW, Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. Ann Allergy. 1993;70:316-22.
11. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW, et al. A comparison of salmeterol with albuterol in the treatment of mild-to- moderate asthma. N Engl J Med. 1992;327:1420-5.
12. Meyer JM, Wenzel CL, Kradjan WA. Salmeterol: a novel, long-acting beta 2-agonist. Ann Pharmacother. 1993;27:1478-87.
13. Maconochie JG, Forster JK. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol. 1992;33:342-5.
14. Lopezguillen A, Marques L, Lopezllorente MT, Pastor E, Figueras A. Salmeterol-induced vertigo. Eur Respir J. 1994;7:2089-90.
15. Barnes PJ. Drug therapy: inhaled glucocorticoids for asthma. N Engl J Med. 1995;332:868-75.
16. Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol. 1996;49:247-50.
17. Product Information. Flovent (fluticasone). Glaxo Wellcome. 2001.
18. Wilkinson JR, Roberts JA, Bradding P, Holgate ST, Howarth PH. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ. 1992;305:931-2.
19. Clark CE, Ferguson AD, Siddorn JA. Respiratory arrests in young asthmatics on salmeterol. Respir Med. 1993;87:227-8.
20. Dottorini ML, Tantucci C, Peccini F, Grassi V, Sorbini CA. Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol. Int J Clin Pharmacol Ther. 1996;34:438-43.
21. Maconochie JG, Minton NA, Chilton JE, Keene ON. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Br J Clin Pharmacol. 1994;37:199-204.
22. Britton MG, Earnshaw JS, Palmer JB. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group [published erratum appears in Eur Respir J 1993;6(1):150]. Eur Respir J. 1992;5:1062-7.
23. Ullman A, Svedmyr N. Salmeterol comparison with salbutamol in adult asthmatic patients. Thorax. 1988;43:674-8.
24. Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G. Short-term cardiovascular effects of salmeterol. Chest. 1998;113:1272-6.
25. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs. 1994;47:318-31.
26. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicenter randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet. 1998;351:773-80.
27. Executive Committee American Academy of Allergy and Immunology. Inhaled corticosteroids and severe viral infections. J Allergy Clin Immunol. 1993;92:223-8.
28. Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM. Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids. Thorax. 1992;47:414-7.
29. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997;277:722-7.
30. Svedmyr N, Lofdahl CG. The use of beta(2)-adrenoceptor agonists in the treatment of bronchial asthma. Pharmacol Toxicol. 1996;78:3-11.
31. Booth H, Bish R, Walters J, Whitehead F, Walters EH. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax. 1996;51:1100-4.
32. Hatton MQ, Allen MB, Mellor EJ, Cooke NJ. Salmeterol rash . Lancet. 1991;337:1169-70.
33. Grahnen A, Eckernas SA, Brundin RM, Lingandersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol. 1994;38:521-5.
34. Howland WC. Fluticasone propionate: topical or systemic effects? Clin Exp Allergy. 1996;26 ( Suppl:18-22.
35. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax. 1997;52:55-8.
36. Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1997;43:155-61.
37. Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med. 1999;160:157-61.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.